Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MDGL Madrigal Pharmaceuticals, Inc.

交易中 12-16 15:16:01 EST

554.33

-6.22

-1.11%

最高559.99	最低544.24	成交量14.36万
今开554.78	昨收560.55	日振幅2.81%
总市值125.90亿	流通市值60.98亿	总股本2,271万
成交额7,902万	换手率1.31%	流通股本1,100万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals, Inc.","latestPrice":554.33,"timestamp":1765916159225,"preClose":560.55,"halted":0,"volume":143581,"delay":0,"floatShares":11000087,"shares":22711420,"eps":-13.035484,"marketStatus":"交易中","change":-6.22,"latestTime":"12-16 15:16:01 EST","open":554.78,"high":559.99,"low":544.24,"amount":79021018.04526001,"amplitude":0.028097,"askPrice":555.5,"askSize":28,"bidPrice":553.18,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-13.035484,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765918800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":560.55,"preHourTrading":{"tag":"盘前","latestPrice":560.23,"preClose":560.55,"latestTime":"08:49 EST","volume":48,"amount":26745.3984,"timestamp":1765892958940},"postHourTrading":{"tag":"盘后","latestPrice":560.55,"preClose":560.55,"latestTime":"19:29 EST","volume":12973,"amount":7271817.26,"timestamp":1765844942689},"volumeRatio":0.611401,"impliedVol":0.5895,"impliedVolPercentile":0.436},"requestUrl":"/m/hq/s/MDGL/wiki","defaultTab":"wiki","newsList":[{"id":"2580724054","title":"Madrigal Pharmaceuticals, Inc.跌4.51% 股价跌破400美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2580724054","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580724054?lang=zh_cn&edition=full","pubTime":"2025-11-03 23:34","pubTimestamp":1762184080,"startTime":"0","endTime":"0","summary":"北京时间2025年11月03日23时34分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价大幅下跌4.51%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.95%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc 是一家生物制药公司，专注于提供代谢功能障碍相关脂肪性肝炎  的新型疗法，这是一种严重的肝病，具有高度未满足的医疗需求，可能导致肝硬化、肝功能衰竭和过早死亡。消息层面，截至23时34分，《美银证券上调Madrigal Pharmaceuticals至持有评级，上调目标价至445美元》资讯为影响Madrigal Pharmaceuticals, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103233440a4857fa5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103233440a4857fa5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4139","MDGL"],"gpt_icon":0},{"id":"2559069993","title":"Madrigal Pharmaceuticals, Inc.8月13日成交额为2.71亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2559069993","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559069993?lang=zh_cn&edition=full","pubTime":"2025-08-14 12:14","pubTimestamp":1755144874,"startTime":"0","endTime":"0","summary":"美东时间2025年8月13日，Madrigal Pharmaceuticals, Inc.成交额为2.71亿美元，成交额较昨日增加56.03%，当日成交量为73.13万股。Madrigal Pharmaceuticals, Inc.于2025年8月13日涨4.03%，报373.46美元，该股过去5个交易日涨10.46%，年初至今涨21.03%，过去60日涨28.35%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814121440a487b13d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814121440a487b13d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4139","MDGL"],"gpt_icon":0},{"id":"2558561875","title":"Madrigal Pharmaceuticals, Inc.8月11日成交额为9557.69万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558561875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558561875?lang=zh_cn&edition=full","pubTime":"2025-08-12 12:06","pubTimestamp":1754971581,"startTime":"0","endTime":"0","summary":"美东时间2025年8月11日，Madrigal Pharmaceuticals, Inc.成交额为9557.69万美元，成交额较昨日减少21.97%，当日成交量为27.40万股。Madrigal Pharmaceuticals, Inc.于2025年8月11日涨1.09%，报349.5美元，该股过去5个交易日涨11.98%，年初至今涨13.26%，过去60日涨23.56%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812120627a483353b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812120627a483353b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDGL","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2558268436","title":"Madrigal Pharmaceuticals, Inc.2025财年第二财季实现净利润-42.28百万美元，同比增加72.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558268436","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558268436?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:01","pubTimestamp":1754841664,"startTime":"0","endTime":"0","summary":"8月11日，Madrigal Pharmaceuticals, Inc.公布财报，公告显示公司2025财年第二财季净利润为-42.28百万美元，同比增加72.18%；其中营业收入为2.13亿美元，同比增加1354.92%，每股基本收益为-1.90美元。从资产负债表来看，Madrigal Pharmaceuticals, Inc.总负债3.19亿美元，其中短期债务1.05百万美元，资产负债比为3.19，流动比率为5.10。机构评级：截至2025年8月11日，当前有14家机构对Madrigal Pharmaceuticals, Inc.目标价做出预测，其中目标均价为436.50美元，其中最低目标价为266.00美元，最高目标价为567.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000226a48056aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000226a48056aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDGL"],"gpt_icon":0},{"id":"2558505210","title":"Madrigal Pharmaceuticals, Inc.8月8日成交额为1.22亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558505210","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558505210?lang=zh_cn&edition=full","pubTime":"2025-08-09 12:04","pubTimestamp":1754712244,"startTime":"0","endTime":"0","summary":"美东时间2025年8月8日，Madrigal Pharmaceuticals, Inc.成交额为1.22亿美元，成交额较昨日减少5.72%，当日成交量为35.54万股。Madrigal Pharmaceuticals, Inc.于2025年8月8日涨1.0%，报345.73美元，该股过去5个交易日涨14.42%，年初至今涨12.04%，过去60日涨17.05%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809120408a47e4c4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809120408a47e4c4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","MDGL","BK4139"],"gpt_icon":0},{"id":"2557124255","title":"Madrigal Pharmaceuticals, Inc.8月7日成交额为1.30亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557124255","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557124255?lang=zh_cn&edition=full","pubTime":"2025-08-08 12:03","pubTimestamp":1754625825,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日，Madrigal Pharmaceuticals, Inc.成交额为1.30亿美元，成交额较昨日增加11.08%，当日成交量为38.15万股。Madrigal Pharmaceuticals, Inc.于2025年8月7日涨1.24%，报342.29美元，该股过去5个交易日涨13.15%，年初至今涨10.93%，过去60日涨13.81%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808120349a47c4efc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808120349a47c4efc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","BK4585","MDGL"],"gpt_icon":0},{"id":"2557041580","title":"Madrigal Pharmaceuticals, Inc.8月6日成交额为1.17亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557041580","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557041580?lang=zh_cn&edition=full","pubTime":"2025-08-07 11:57","pubTimestamp":1754539055,"startTime":"0","endTime":"0","summary":"美东时间2025年8月6日，Madrigal Pharmaceuticals, Inc.成交额为1.17亿美元，成交额较昨日减少71.71%，当日成交量为34.66万股。Madrigal Pharmaceuticals, Inc.于2025年8月6日跌0.24%，报338.11美元，该股过去5个交易日涨16.64%，年初至今涨9.57%，过去60日涨14.75%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807115742a47a02f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807115742a47a02f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4139","MDGL"],"gpt_icon":0},{"id":"2557637618","title":"MASH新药上半年大卖3.5亿美元，全年预计8亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557637618","media":"医药魔方Info","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557637618?lang=zh_cn&edition=full","pubTime":"2025-08-06 18:15","pubTimestamp":1754475342,"startTime":"0","endTime":"0","summary":"8月5日，Madrigal Pharmaceuticals发布2025年第二季度业绩，Rezdiffra大卖2.128亿美元，环比增长55%，上半年总计销售额为3.501亿美元。基于此，Madrigal Pharmaceuticals预计该产品的全年销售额可以达到8亿+美元。2008年12月，VIA Pharmaceuticals与罗氏达成协议，获得了该药物的所有权益。2011年9月，Madrigal Pharmaceuticals出手收购了Resmetirom。五年后，Madrigal Pharmaceuticals开始在临床试验中评估该药物在MASH人群中的治疗潜力。经过八年的探索后，Resmetirom在2024年3月基于III期MAESTRO-NASH研究的积极结果获得FDA批准上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806192051a478a0df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806192051a478a0df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDGL","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2557106342","title":"Madrigal Pharmaceuticals, Inc.8月5日成交额为4.13亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557106342","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557106342?lang=zh_cn&edition=full","pubTime":"2025-08-06 11:50","pubTimestamp":1754452231,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日，Madrigal Pharmaceuticals, Inc.成交额为4.13亿美元，成交额较昨日增加226.93%，当日成交量为123.32万股。Madrigal Pharmaceuticals, Inc.于2025年8月5日涨8.59%，报338.91美元，该股过去5个交易日涨15.12%，年初至今涨9.83%，过去60日涨13.13%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806115037a477d331&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806115037a477d331&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4585","MDGL"],"gpt_icon":0},{"id":"2557351778","title":"Madrigal Pharmaceuticals, Inc.8月4日成交额为1.26亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557351778","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557351778?lang=zh_cn&edition=full","pubTime":"2025-08-05 11:50","pubTimestamp":1754365817,"startTime":"0","endTime":"0","summary":"美东时间2025年8月4日，Madrigal Pharmaceuticals, Inc.成交额为1.26亿美元，成交额较昨日增加76.81%，当日成交量为40.49万股。Madrigal Pharmaceuticals, Inc.于2025年8月4日涨3.29%，报312.11美元，该股过去5个交易日涨6.1%，年初至今涨1.15%，过去60日涨4.44%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805115019a6d39f1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805115019a6d39f1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","MDGL","BK4585","BK4139"],"gpt_icon":0},{"id":"2556847634","title":"Madrigal Pharmaceuticals, Inc.8月1日成交额为7151.33万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556847634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556847634?lang=zh_cn&edition=full","pubTime":"2025-08-02 11:53","pubTimestamp":1754106792,"startTime":"0","endTime":"0","summary":"美东时间2025年8月1日，Madrigal Pharmaceuticals, Inc.成交额为7151.33万美元，成交额较昨日减少55.88%，当日成交量为23.68万股。Madrigal Pharmaceuticals, Inc.于2025年8月1日跌0.11%，报302.17美元，该股过去5个交易日涨1.26%，年初至今跌2.07%，过去60日涨2.39%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802115318a6cecb33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802115318a6cecb33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","BK4585","MDGL"],"gpt_icon":0},{"id":"2556866044","title":"Madrigal Pharmaceuticals, Inc.7月31日成交额为1.62亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556866044","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556866044?lang=zh_cn&edition=full","pubTime":"2025-08-01 11:48","pubTimestamp":1754020104,"startTime":"0","endTime":"0","summary":"美东时间2025年7月31日，Madrigal Pharmaceuticals, Inc.成交额为1.62亿美元，成交额较昨日增加3.52%，当日成交量为53.55万股。Madrigal Pharmaceuticals, Inc.于2025年7月31日涨4.36%，报302.51美元，该股过去5个交易日涨1.12%，年初至今跌1.96%，过去60日跌1.26%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801114826a6cce563&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801114826a6cce563&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4585","MDGL"],"gpt_icon":0},{"id":"2555025330","title":"Madrigal制药公司与CSPC就口服GLP-1激动剂达成协议Madrigal Pharmaceuticals Enters into Agreement with CSPC for Oral GLP-1 Agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2555025330","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555025330?lang=zh_cn&edition=full","pubTime":"2025-07-31 15:28","pubTimestamp":1753946880,"startTime":"0","endTime":"0","summary":"The agreement supports Madrigal’s strategy to strengthen its pipeline in metabolic dysfunction-associated steatohepatitis . The company sees potential in combining SYH2086 with its approved drug, Rezdiffra, to create a once-daily oral treatment that addresses both weight reduction and liver health. .该协议支持了Madrigal加强其在代谢功能障碍相关脂肪性肝炎领域产品线的战略。CSPC expressed confidence in Madrigal’s ability to advance SYH2086 through development and deliver benefits to patients globally.石药集团表示，相信Madrigal公司有能力推动SYH2086的研发，并为全球患者带来益处。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731154235972988ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731154235972988ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDGL","BK4588","BK4144","GLP","BK4585","01093","BK4139","BK4590"],"gpt_icon":0},{"id":"2555010337","title":"石药集团：与MADRIGAL就SYH2086订立独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2555010337","media":"金吾资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555010337?lang=zh_cn&edition=full","pubTime":"2025-07-30 17:16","pubTimestamp":1753867011,"startTime":"0","endTime":"0","summary":"根据该协议的条款，石药同意授予Madrigal在全球范围内开发、生产及商业化SYH2086的独家授权，同时保留本集团 在中国开发和销售其他口服小分子GLP -1 受体激动剂产品的权益。石药集团有权收取最高可达 20.75 亿美元的总代价，包括1.2亿美元的预付款、 最高可达19.55亿美元的潜在开发、监管及商业里程碑付款，以及基于SYH2086年度净销售额的高达双位数销售提成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730172428972775b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730172428972775b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","BK4585","MDGL"],"gpt_icon":0},{"id":"2555091352","title":"Madrigal Pharmaceuticals, Inc.7月29日成交额为7634.56万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555091352","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555091352?lang=zh_cn&edition=full","pubTime":"2025-07-30 11:54","pubTimestamp":1753847687,"startTime":"0","endTime":"0","summary":"美东时间2025年7月29日，Madrigal Pharmaceuticals, Inc.成交额为7634.56万美元，成交额较昨日减少12.01%，当日成交量为25.99万股。Madrigal Pharmaceuticals, Inc.于2025年7月29日涨0.08%，报294.4美元，该股过去5个交易日跌6.06%，年初至今跌4.59%，过去60日跌10.16%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730115455a46ac413&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730115455a46ac413&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","MDGL","BK4139"],"gpt_icon":0},{"id":"2555775089","title":"Madrigal Pharmaceuticals, Inc.7月28日成交额为8676.36万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555775089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555775089?lang=zh_cn&edition=full","pubTime":"2025-07-29 11:52","pubTimestamp":1753761161,"startTime":"0","endTime":"0","summary":"美东时间2025年7月28日，Madrigal Pharmaceuticals, Inc.成交额为8676.36万美元，成交额较昨日减少3.23%，当日成交量为29.25万股。Madrigal Pharmaceuticals, Inc.于2025年7月28日跌1.42%，报294.16美元，该股过去5个交易日跌11.11%，年初至今跌4.67%，过去60日跌11.9%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729115244a468d480&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729115244a468d480&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MDGL","BK4585","BK4588"],"gpt_icon":0},{"id":"2554671337","title":"Madrigal Pharmaceuticals, Inc.7月25日成交额为8966.06万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554671337","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554671337?lang=zh_cn&edition=full","pubTime":"2025-07-26 11:49","pubTimestamp":1753501782,"startTime":"0","endTime":"0","summary":"美东时间2025年7月25日，Madrigal Pharmaceuticals, Inc.成交额为8966.06万美元，成交额较昨日减少17.75%，当日成交量为30.00万股。Madrigal Pharmaceuticals, Inc.于2025年7月25日跌0.26%，报298.4美元，该股过去5个交易日跌10.69%，年初至今跌3.3%，过去60日跌12.44%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726114943a4643ca7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726114943a4643ca7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","MDGL","BK4588","BK4139"],"gpt_icon":0},{"id":"2554775390","title":"Madrigal Pharmaceuticals, Inc.7月24日成交额为1.09亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554775390","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554775390?lang=zh_cn&edition=full","pubTime":"2025-07-25 11:42","pubTimestamp":1753414936,"startTime":"0","endTime":"0","summary":"美东时间2025年7月24日，Madrigal Pharmaceuticals, Inc.成交额为1.09亿美元，成交额较昨日减少6.85%，当日成交量为36.01万股。Madrigal Pharmaceuticals, Inc.于2025年7月24日跌2.47%，报299.17美元，该股过去5个交易日跌14.21%，年初至今跌3.05%，过去60日跌9.7%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725114226a462715c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725114226a462715c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDGL","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2553293775","title":"Madrigal Pharmaceuticals, Inc.7月22日成交额为1.85亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553293775","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553293775?lang=zh_cn&edition=full","pubTime":"2025-07-23 11:41","pubTimestamp":1753242118,"startTime":"0","endTime":"0","summary":"美东时间2025年7月22日，Madrigal Pharmaceuticals, Inc.成交额为1.85亿美元，成交额较昨日增加140.59%，当日成交量为58.35万股。Madrigal Pharmaceuticals, Inc.于2025年7月22日跌5.3%，报313.4美元，该股过去5个交易日涨0.73%，年初至今涨1.57%，过去60日跌2.04%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723114159a45dd893&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723114159a45dd893&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4139","MDGL"],"gpt_icon":0},{"id":"2553286421","title":"Madrigal Pharmaceuticals, Inc.7月21日成交额为7686.17万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553286421","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553286421?lang=zh_cn&edition=full","pubTime":"2025-07-22 11:40","pubTimestamp":1753155606,"startTime":"0","endTime":"0","summary":"美东时间2025年7月21日，Madrigal Pharmaceuticals, Inc.成交额为7686.17万美元，成交额较昨日减少30.07%，当日成交量为23.22万股。Madrigal Pharmaceuticals, Inc.于2025年7月21日跌0.95%，报330.94美元，该股过去5个交易日涨3.46%，年初至今涨7.25%，过去60日涨7.17%。该公司的药物 Rezdiffra  是一种每日一次、口服、肝脏靶向的甲状腺激素受体激动剂，旨在针对 MASH 的关键根本原因。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722114009a6b9aa92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722114009a6b9aa92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4585","MDGL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":-0.0141},{"period":"1month","weight":0.0592},{"period":"3month","weight":0.3126},{"period":"6month","weight":0.9827},{"period":"1year","weight":0.8409},{"period":"ytd","weight":0.8166}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Madrigal Pharmaceuticals, Inc.于2000年3月成立并在2001年7月开始运营。 Synta制药公司是一家生物制药公司，致力于发现、开发和商业化小分子药物以扩大和加强带有严重疾病的患者的生命，包括癌症和慢性症性疾病。该公司有两种候选药物在临床实验中用于治疗多种类型的癌症和几个用于临床前研究阶段的候选药物。所有公司的候选药物利用公司的专利、独特的化合物和集成的发现引擎发现。这家公司保留了其候选药物的全部选择权。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.038123},{"month":2,"riseRate":0.777778,"avgChangeRate":0.080513},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.037813},{"month":4,"riseRate":0.555556,"avgChangeRate":0.008622},{"month":5,"riseRate":0.333333,"avgChangeRate":0.130548},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032539},{"month":7,"riseRate":0.111111,"avgChangeRate":-0.07894},{"month":8,"riseRate":0.6,"avgChangeRate":0.097087},{"month":9,"riseRate":0.4,"avgChangeRate":0.124291},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.36855}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals, Inc.","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Madrigal Pharmaceuticals, Inc.(MDGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Madrigal Pharmaceuticals, Inc.,MDGL,Madrigal Pharmaceuticals, Inc.股票,Madrigal Pharmaceuticals, Inc.股票老虎,Madrigal Pharmaceuticals, Inc.股票老虎国际,Madrigal Pharmaceuticals, Inc.行情,Madrigal Pharmaceuticals, Inc.股票行情,Madrigal Pharmaceuticals, Inc.股价,Madrigal Pharmaceuticals, Inc.股市,Madrigal Pharmaceuticals, Inc.股票价格,Madrigal Pharmaceuticals, Inc.股票交易,Madrigal Pharmaceuticals, Inc.股票购买,Madrigal Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Madrigal Pharmaceuticals, Inc.(MDGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}